NEW YORK--() May 10, 2013 -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the first quarter ended March 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
·On January 2, 2013, Synergy announced positive results from its large multicenter clinical trial of its lead investigational drug plecanatide in patients with CIC.
·On January 17, 2013, Synergy completed its merger with Callisto Pharmaceuticals, Inc.
·On March 15, 2013, Synergy announced that the full study results from its large multicenter CIC clinical trial would be featured in a late-breaking oral presentation session at Digestive Disease Week 2013 in Orlando, Florida on Tuesday, May 21, 2013.
·On April 16, 2013, Synergy closed a public offering of 16,375,000 shares of its common stock at a price of $5.50 per share, less underwriting discounts and commissions. The net proceeds to Synergy from this sale was approximately $84.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Synergy. (Pro-forma Balance Sheets below)
Synergy's cash, cash equivalents and short term available for sale securities balance as of March 31, 2013 was $21.1 million, as compared to $32.5 million on December 31, 2012. During the three months ended March 31, 2013 net cash provided by financing activities was $4.6 million from the controlled equity sales of its common stock, whereas there was no such financing activity during the three months ended March 31, 2012. Net cash used in operating activities during the three months ended March 31, 2013 and 2012 was $15.6 million and $6.8 million, respectively.
Net loss for the three months ended March 31, 2013 was $18.7 million or $0.26 per share, as compared to a net loss of $7.0 million, or $0.13 per share, for the three months ended March 31, 2012. During the three months ended March 31, 2012 non-cash expense items, principally the change in fair value of derivative instruments and share based compensation expense, totaled $2.4 million, or $0.03 per share, whereas such items in the three months ended March 31, 2012 totaled $.4 million, or $0.01 per share.
Synergy had approximately 73.8 million common shares outstanding at March 31, 2013.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy‘s lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal (GI) hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy previously completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in CIC patients. On January 2, 2013, Synergy announced positive results in a Phase II/III large multicenter clinical trial of plecanatide to treat CIC. Plecanatide is also being developed to treat patients with IBS-C. Synergy’s second GC-C agonist SP-333 is in clinical development to treat inflammatory bowel diseases, and is presently in a Phase I trial in healthy volunteers. More information is available atSynergy Pharmaceuticals Reports First Quarter 2013 Financial Results
BEDFORD, MASS.--( / ) June 24, 2020 -- PostgreSQL adoption is exploding worldwide. As its popularity continues to rise, EDB has updated its brand to better reflect its 야튜브 1+1은귀요미섹시 mission to bring PostgreSQL to more organizations. Unveiled today during the Postgres Vision 2020 virtual conference, the rebrand includes a name change to EDB fueled by a company transformation that conveys a steadfast commitment to help organizations accelerate innovation using PostgreSQL. To learn 야튜브 페이스북귀요미송노출 more about the rebrand, visit the 이번주로또예상 BEDFORD,website().
PostgreSQL is a 라싱산탄데르 PostgreSQL야튜브 음란서생 Changer 야튜브 섹시귀요미송3탄
PostgreSQL is open source 개조아 PostgreSQLat its best, fundamentally 야튜브 changing IT economics. Teams everywhere are deploying it on-premises, in containers, and in the cloud. It’s also governed by volunteers from around the world who are focused on delivering high quality software and enabling faster innovation. And while PostgreSQL offers strong capabilities that enable a wide range of applications, everyone from database administrators and developers to architects and DevOps managers can use some help to plug in and go faster.
“Postgres is bigger than any one company. It’s a 야튜브 해수욕장 movement. Our new tagline, ‘Power to Postgres,’ captures both the spirit of that movement and our commitment to 야튜브 tkx it,” says EDB president and CEO Ed 일본아마존 “Postgres“We’re database fanatics, and for our customers, a trusted partner with the energy and expertise to supercharge Postgres and help them overcome their 야튜브 화성인i컵녀 challenges.”
According to Adam Bunch, director of engineering and architecture for Konica Minolta Healthcare Americas, “EDB is like a member of our team who works with us to figure 야튜브 일노출녀 out our best path forward and how 야튜브 최고노출녀 to get more from Postgres. They are experts who 소라넷 Accordinglean on 24x7 to help us run our business, as well as a strategic partner who has been instrumental in keeping our customers happy. Their expertise has been invaluable.”
EDB also extends PostgreSQL through a network of global partnerships. For example, last year, 야튜브 비키니할인 EDB began partnering with IBM to offer EDB Postgres Advanced 소라넷 EDB(EPAS) as part of the IBM Data Management Platform. In an 소라넷 EDB생카지노 EDBtheir partnership, the companies recently announced that EPAS will be available as a database-as-a-service on IBM Cloud within the next few weeks.
“EDB is a key strategic partner, further enriching the IBM Cloud ecosystem and helping us offer 야튜브 아이유찌지 the best database technologies,” 모가미카스미 “EDBPhil Buckellew, General Manager, IBM Cloud Platform. “EDB is committed to helping organizations get more from Postgres. This is vital as IBM Cloud seeks to provide even greater support for the open source 야튜브 달린다 community and further drive open innovation.”
EDB is a leader 야튜브 일반인노래레전드 in the database management market with a passion for PostgreSQL, both where it’s 스트림클럽 EDBand where it’s going. In addition to Konica Minolta Healthcare Americas, the company serves organizations such as IKEA, who uses EPAS and 야튜브 EDB Support, and Mastercard, who uses EDB replication software. All three organizations are 자위 EDBsessions this week at Postgres Vision 2020.
Visit 야한동영상사이트 Visitto 야튜브 일반인검정스타킹 learn more about PostgreSQL for people, teams, 야튜브 일반인팬티스타킹 and enterprises.
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get 나안동홀덤 PostgreSQLmost out of it both 야튜브 치마속팬티모음 on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices KYUT PostgreSQLEDB serves over 4,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com.
View 세종로맞고 View야튜브 version on 야튜브 businesswire.com:Korea Newswire distributes your news across every media channels through the 야튜브 여자꼬시는법 industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.